BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22425775)

  • 1. Heregulin-β1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway.
    Ruan SQ; Wang ZH; Wang SW; Fu ZX; Xu KL; Li DB; Zhang SZ
    Biochem Biophys Res Commun; 2012 Apr; 420(2):385-90. PubMed ID: 22425775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of HRG-β1-induced proliferation, migration and invasion of MCF-7 cells by upregulation of GPR30 expression.
    Ruan SQ; Wang SW; Wang ZH; Zhang SZ
    Mol Med Rep; 2012 Jul; 6(1):131-8. PubMed ID: 22576740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
    Tan M; Grijalva R; Yu D
    Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration.
    Bourguignon LY; Gilad E; Peyrollier K
    J Biol Chem; 2007 Jul; 282(27):19426-41. PubMed ID: 17493932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HRG-β1-driven ErbB3 signaling induces epithelial-mesenchymal transition in breast cancer cells.
    Kim J; Jeong H; Lee Y; Kim C; Kim H; Kim A
    BMC Cancer; 2013 Aug; 13():383. PubMed ID: 23937725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration.
    Xiong S; Grijalva R; Zhang L; Nguyen NT; Pisters PW; Pollock RE; Yu D
    Cancer Res; 2001 Feb; 61(4):1727-32. PubMed ID: 11245489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
    Filardo EJ; Quinn JA; Frackelton AR; Bland KI
    Mol Endocrinol; 2002 Jan; 16(1):70-84. PubMed ID: 11773440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol inhibits heregulin-beta1-mediated matrix metalloproteinase-9 expression and cell invasion in human breast cancer cells.
    Tang FY; Chiang EP; Sun YC
    J Nutr Biochem; 2008 May; 19(5):287-94. PubMed ID: 17651959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway.
    Stoica GE; Franke TF; Wellstein A; Morgan E; Czubayko F; List HJ; Reiter R; Martin MB; Stoica A
    Oncogene; 2003 Apr; 22(14):2073-87. PubMed ID: 12687010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
    Awasthi S; Hamburger AW
    J Cell Physiol; 2014 Nov; 229(11):1831-41. PubMed ID: 24692179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
    Yang C; Liu Y; Lemmon MA; Kazanietz MG
    Mol Cell Biol; 2006 Feb; 26(3):831-42. PubMed ID: 16428439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
    Lee H; Akita RW; Sliwkowski MX; Maihle NJ
    Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.
    Filardo EJ; Quinn JA; Bland KI; Frackelton AR
    Mol Endocrinol; 2000 Oct; 14(10):1649-60. PubMed ID: 11043579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
    Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
    Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway.
    St-Laurent V; Sanchez M; Charbonneau C; Tremblay A
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):23-37. PubMed ID: 15862947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baicalein suppresses 17-β-estradiol-induced migration, adhesion and invasion of breast cancer cells via the G protein-coupled receptor 30 signaling pathway.
    Shang D; Li Z; Zhu Z; Chen H; Zhao L; Wang X; Chen Y
    Oncol Rep; 2015 Apr; 33(4):2077-85. PubMed ID: 25672442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen stimulated migration and invasion of estrogen receptor-negative breast cancer cells involves an ezrin-dependent crosstalk between G protein-coupled receptor 30 and estrogen receptor beta signaling.
    Zhou K; Sun P; Zhang Y; You X; Li P; Wang T
    Steroids; 2016 Jul; 111():113-120. PubMed ID: 26850467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The membrane estrogen receptor GPR30 mediates cadmium-induced proliferation of breast cancer cells.
    Yu X; Filardo EJ; Shaikh ZA
    Toxicol Appl Pharmacol; 2010 May; 245(1):83-90. PubMed ID: 20153348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines.
    Hijazi MM; Thompson EW; Tang C; Coopman P; Torri JA; Yang D; Mueller SC; Lupu R
    Int J Oncol; 2000 Oct; 17(4):629-41. PubMed ID: 10995872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.